Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL434419 | 0.87 | TLR7 (0.33) | TLR7 | |
| SCHEMBL12157588 | 0.87 | NCF1 (0.34) | TLR7 | |
| SCHEMBL731519 | 0.85 | TLR7 (0.41) | TLR7 | |
| SCHEMBL2542341 | 0.85 | TLR7 (0.41) | TLR7 | |
| SCHEMBL4298076 | 0.84 | MEN1 (0.39) | MEN1KMT2ACYP1A2MAT2AADORA2A | |
| SCHEMBL31124723 | 0.84 | SLC29A1 (0.35) | ADORA2AADORA2BTLR7 | |
| SCHEMBL2201765 | 0.83 | TLR8 (0.35) | ADORA2AADORA2B | |
| SCHEMBL10383664 | 0.82 | KMT2A (0.36) | PDE4BPDE4DMEN1KMT2ACYP1A2 | |
| SCHEMBL31126581 | 0.81 | TLR7 (0.39) | ADORA2AADORA2BTLR7 | |
| SCHEMBL12157553 | 0.81 | ADORA2A (0.38) | ADORA2AADORA2BTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012011606-A1 | PROCESS FOR PREPARING ADENINE COMPOUNDS AND INTERMEDIATES THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-01-26 | — | — | WO | disclosed |
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2133353-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028715-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | PDE4B 3371/4885PDE4D 4166/4885MEN1 3398/4885 |
| US-20100093998-A1 | NOVEL ADENINE COMPOUND | NR0B2, NR0B1, BRD7 | PDE4B 3334/4885PDE4D 4152/4885MEN1 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.